Supplementary Figure from Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma
Margarete M. Karg(Massachusetts Eye and Ear Infirmary), Jacobus J. Bosch(Friedrich-Alexander-Universität Erlangen-Nürnberg), Yazid J. Resheq(Friedrich-Alexander-Universität Erlangen-Nürnberg), Christian Buettner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Barbara Bock(Friedrich-Alexander-Universität Erlangen-Nürnberg), Nasrin Refaian(Integrated Oncology (United States)), Tanja Rottmar(Friedrich-Alexander-Universität Erlangen-Nürnberg), Andréas Mackensen(University Medical Center Freiburg), Bruce R. Ksander(Massachusetts Eye and Ear Infirmary), Lukas John(University of Hohenheim), Jonas Sommer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ludwig M. Heindl(University of Cologne)
Cited by 0
Related Papers
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
NLRP3 Inflammasome Activation in Retinal Pigment Epithelial Cells by Lysosomal Destabilization: Implications for Age-Related Macular Degeneration
|Investigative Ophthalmology & Visual Science|2012|285
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
|The Lancet Haematology|2019|247
Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells
|Cancer Immunology Immunotherapy|2000|240
Advancements and challenges in CAR T cell therapy in autoimmune diseases
|Nature Reviews Rheumatology|2024|203